Results 191 to 200 of about 58,085 (295)

Combined Dipeptidyl Peptidase 4 Inhibitor and α-Glucosidase Inhibitor Treatment in Postprandial Hypoglycemia. [PDF]

Clin Diabetes, 2022
Broome DT, Kodali A, Phillips D, Makin V, Mendlovic D, Zimmerman RS.   +5 more
europepmc   +1 more source

Association of Hemoglobin A_1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin [PDF]

, 2018
Rohit Vashisht, Kenneth A. Jung, Alejandro Schuler, Juan M. Banda, Rae Woong Park, Sanghyung Jin, Li Li, Joel T. Dudley, Kipp W. Johnson, Mark Shervey, Hua Xu, Yonghui Wu, Karthik Natrajan, George Hripcsak, Peng Jin, Mui Van Zandt, Anthony Reckard, Christian Reich, James Weaver, Martijn J. Schuemie, Patrick Ryan, Alison Callahan, Nigam H. Shah   +22 more
openalex   +1 more source

A case report of dipeptidyl peptidase 4 inhibitor-related kidney disease combined with renal cancer. [PDF]

Front Nephrol
Kurihara S, Sawa N, Sumida K, Ikuma D, Oba Y, Mizuno H, Sekine A, Yamanouchi M, Hasegawa E, Suwabe T, Urakami S, Kono K, Kinowaki K, Ohashi K, Yamaguchi Y, Ubara Y.   +15 more
europepmc   +1 more source

Cost–Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden [PDF]

, 2014
Ali Kiadaliri, Ulf‐G. Gerdtham, Björn Eliasson, Katarina Steen Carlsson   +3 more
openalex   +1 more source

Association between the body mass index and risk of cardiovascular events in sodium-glucose cotransporter 2 inhibitor users compared with dipeptidyl-peptidase 4 inhibitor users: A nationwide cohort study in Korea. [PDF]

Diabetes Obes Metab
Ko HY, Jung K, Cho Y, Bea S, Bae JH, Cho YM, Rhee SY, Shin JY.   +7 more
europepmc   +1 more source

The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Ameliorates Endothelial Inflammation and Microvascular Thrombosis in a Sepsis Mouse Model. [PDF]

Int J Mol Sci, 2022
Wang SC, Wang XY, Liu CT, Chou RH, Chen ZB, Huang PH, Lin SJ.   +6 more
europepmc   +1 more source

Efficacy of omarigliptin, once-weekly dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes. [PDF]

World J Diabetes, 2021
Kawasaki E, Nakano Y, Fukuyama T, Uchida A, Sagara Y, Tamai H, Tojikubo M, Hiromatsu Y, Koga N.   +8 more
europepmc   +1 more source

Pharmacokinetic, pharmacodynamic and clinical evaluation of saxagliptin in type 2 diabetes [PDF]

, 2016
Jeffrey Stephens
core   +1 more source

QSAR rationales for the dipeptidyl peptidase-4 (DPP-4) inhibitors: The imidazolopyrimidine amides

, 2020
Raghuraj Parihar, Sharma Brij Kishore
openalex   +1 more source

Dipeptidyl peptidase‐4 inhibitor approaches

Journal of Diabetes, 2016
openaire   +1 more source